GleamWall
中文EN

TCRX TScan Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1783328 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-38.4%
TTM net income YoY19.3%
TTM EPS YoY20.5%
Revenue 3-yr CAGR-32.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,246.8%
Net margin-2,219.2%
FCF margin-2,153.3%
EBITDA margin-2,192.3%

Returns

ROE-126.4%
ROA-57.0%
ROIC (approx.)-3,777.3%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets73.1%
Debt / equity0.87x
Current ratio2.03x
Interest coverage-40.67x

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue14.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$586,000$1.05M$982,000$2.57M$2.51M$3.08M$2.17M$665,000
R&D expense$25.29M$23.40M$21.90M$20.04M$31.69M$32.63M$29.79M$29.35M
SG&A expense$8.33M$8.14M$8.22M$6.39M$7.87M$9.10M$8.63M$8.02M
Operating income-$33.03M-$30.49M-$29.14M-$23.86M-$37.05M-$38.65M-$36.25M-$36.71M
Interest expense$775,000$699,000$689,000$702,000$699,000$689,000$679,000$784,000
Net income-$33.09M-$30.36M-$28.67M-$22.98M-$35.71M-$36.95M-$34.13M-$35.81M
EBITDA-$32.35M-$29.79M-$28.45M-$23.10M-$36.28M-$37.95M-$35.57M-$36.01M
EPS (basic)-0.25-0.23-0.22—-0.28-0.28-0.26—
EPS (diluted)-0.25-0.23-0.22—-0.28-0.28-0.26—
Weighted avg. shares (diluted)130.03M129.95M129.91M—129.84M129.73M129.68M—
Balance sheet
Cash & equivalents$73.04M$100.16M$128.06M$152.41M$169.51M$169.39M$154.11M$183.72M
Short-term investments————$14.95M$48.65M$97.58M$111.42M
Current assets$76.78M$104.40M$132.77M$157.21M$188.16M$221.13M$254.84M$292.72M
PP&E, net$7.11M$7.74M$8.12M$8.71M$9.30M$9.52M$8.35M$7.24M
Total assets$141.40M$171.45M$201.99M$228.79M$262.23M$298.56M$332.71M$371.12M
Current liabilities$37.82M$30.96M$19.97M$18.70M$29.21M$31.32M$29.82M$35.96M
Short-term debt$15.70M$11.71M——————
Long-term debt$17.27M$21.07M$32.65M$32.53M$32.41M$32.30M$32.18M$32.07M
Total debt$32.97M$32.78M$32.65M$32.53M$32.41M$32.30M$32.18M$32.07M
Total liabilities$103.39M$102.43M$105.07M$105.67M$118.20M$121.85M$122.51M$130.15M
Shareholders' equity$38.01M$69.02M$96.92M$123.12M$144.02M$176.71M$210.20M$240.97M
Net debt-$40.07M-$67.38M-$95.40M-$119.87M-$137.09M-$137.10M-$121.93M-$151.65M
Cash flow statement
Operating cash flow-$27.08M-$27.54M-$24.28M-$32.00M-$32.46M-$33.27M-$37.59M-$27.41M
Capital expenditure$41,000$493,000$70,000$171,000$1.43M$1.28M$1.53M$888,000
Free cash flow-$27.12M-$28.03M-$24.35M-$32.17M-$33.89M-$34.55M-$39.12M-$28.30M
Investing cash flow-$41,000-$465,000-$70,000$14.83M$32.58M$48.44M$13.53M$27.29M
Financing cash flow$0——$73,000$0$116,000-$525,000$45.69M
Depreciation & amortization$678,000$699,000$693,000$757,000$767,000$698,000$678,000$703,000
Stock-based compensation$2.08M$2.36M$2.46M$2.01M$3.01M$3.27M$3.41M$2.71M

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.